{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T21:33:18Z","timestamp":1793568798851,"version":"4.5.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Glutathione is a tripeptide synthesized at cytosolic level, that exists in cells in a reduced form (thiol-reduced-GSH-) and in an oxidized form (disulfide-oxidized). The antioxidant function of GSH has led to speculation about its therapeutic role in numerous chronic diseases characterized by altered redox balance and reduced GSH levels, including, for instance, neurodegenerative disorders, cancer, and chronic liver diseases. Among these latter, non-alcoholic fatty liver disease (NAFLD), characterized by lipid accumulation in hepatocytes, in the absence of alcohol abuse or other steatogenic factors, is one of the most prevalent. The umbrella term NAFLD includes the pure liver fat accumulation, the so-called hepatic steatosis or non-alcoholic fatty liver, and the progressive form with inflammation, also known as non-alcoholic steatohepatitis, which is related to the increase in oxidative stress and reactive oxygen species, eventually leading to liver fibrosis. Although the pathogenetic role of oxidative stress in these diseases is well established, there is still limited evidence on the therapeutic role of GSH in such conditions. Hence, the aim of this review is to depict the current molecular and pharmacological knowledge on glutathione, focusing on the available studies related to its therapeutic activity in NAFLD.<\/jats:p>","DOI":"10.3389\/fmed.2023.1124275","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T15:34:02Z","timestamp":1679499242000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":68,"title":["Glutathione: Pharmacological aspects and implications for clinical use in non-alcoholic fatty liver disease"],"prefix":"10.3389","volume":"10","author":[{"given":"Giovanni","family":"Santacroce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Vincenzo","family":"Lenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"ref1","first-page":"8","article-title":"Glutathione!","volume":"13","author":"Pizzorno","year":"2014","journal-title":"Integr Med (Encinitas)"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000443344","article-title":"EASL-EASD-EASO clinical practice guidelines for the Management of non-Alcoholic Fatty Liver Disease","volume":"9","year":"2016","journal-title":"Obes Facts"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"International consensus panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"9547613","DOI":"10.1155\/2018\/9547613","article-title":"Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease","volume":"2021","author":"Masarone","year":"2021","journal-title":"Oxidative Med Cell Longev"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1016\/j.bbagen.2012.09.008","article-title":"Glutathione synthesis","volume":"1830","author":"Lu","year":"1830","journal-title":"Biochim Biophys Acta"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mam.2008.08.006","article-title":"Glutathione: overview of its protective roles, measurement, and biosynthesis","volume":"30","author":"Forman","year":"2009","journal-title":"Mol Asp Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.bioorg.2011.08.004","article-title":"The ATP-grasp enzymes","volume":"39","author":"Fawaz","year":"2011","journal-title":"Bioorg Chem"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.molbiopara.2009.12.011","article-title":"Structure of Trypanosoma brucei glutathione synthetase: domain and loop alterations in the catalytic cycle of a highly conserved enzyme","volume":"170","author":"Fyfe","year":"2010","journal-title":"Mol Biochem Parasitol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/mnfr.201500031","article-title":"L-cysteine metabolism and its nutritional implications","volume":"60","author":"Yin","year":"2016","journal-title":"Mol Nutr Food Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/jn\/134.3.489","article-title":"Glutathione metabolism and its implications for health","volume":"134","author":"Wu","year":"2004","journal-title":"J Nutr"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.freeradbiomed.2016.02.028","article-title":"The role of glutathione reductase and related enzymes on cellular redox homoeostasis network","volume":"95","author":"Couto","year":"2016","journal-title":"Free Radic Biol Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1136\/jech-2014-203861","article-title":"Hormesis and public health: can glutathione depletion and mitochondrial dysfunction due to very low-dose chronic exposure to persistent organic pollutants be mitigated?","volume":"69","author":"Lee","year":"2015","journal-title":"J Epidemiol Community Health"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.mito.2013.01.008","article-title":"Mitochondrial metabolism of reactive oxygen species","volume":"13","author":"Venditti","year":"2013","journal-title":"Mitochondrion"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1016\/j.bbagen.2012.11.020","article-title":"Glutathione peroxidases","volume":"1830","author":"Brigelius-Floh\u00e9","year":"1830","journal-title":"Biochim Biophys Acta"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1006\/bbrc.2000.2800","article-title":"Mitochondrial GPx1 decreases induced but not basal oxidative damage to mtDNA in T47D cells","volume":"272","author":"Legault","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1152\/physrev.1979.59.3.527","article-title":"Hydroperoxide metabolism in mammalian organs","volume":"59","author":"Chance","year":"1979","journal-title":"Physiol Rev"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.molcel.2012.09.025","article-title":"Physiological roles of mitochondrial reactive oxygen species","volume":"48","author":"Sena","year":"2012","journal-title":"Mol Cell"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0006-2952(03)00504-5","article-title":"The changing faces of glutathione, a cellular protagonist","volume":"66","author":"Pompella","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3389\/fphar.2014.00151","article-title":"Glutathione and mitochondria","volume":"5","author":"Ribas","year":"2014","journal-title":"Front Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/0304-4165(88)90038-4","article-title":"Retention of oxidized glutathione by isolated rat liver mitochondria during hydroperoxide treatment","volume":"964","author":"Olafsdottir","year":"1988","journal-title":"Biochim Biophys Acta"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0006-2952(02)01175-9","article-title":"Glutathionylation of proteins by glutathione disulfide S-oxide","volume":"64","author":"Huang","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3109\/03602532.2011.552913","article-title":"Mitochondrial glutathione transferases involving a new function for membrane permeability transition pore regulation","volume":"43","author":"Aniya","year":"2011","journal-title":"Drug Metab Rev"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1515\/BC.2009.033","article-title":"Glutathione dysregulation and the etiology and progression of human diseases","volume":"390","author":"Ballatori","year":"2009","journal-title":"Biol Chem"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.3390\/nu11092073","article-title":"A review of dietary (Phyto) nutrients for glutathione support","volume":"11","author":"Minich","year":"2019","journal-title":"Nutrients"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0278-5846(96)00103-0","article-title":"Reduced intravenous glutathione in the treatment of early Parkinson's disease","volume":"20","author":"Sechi","year":"1996","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00394-014-0706-z","article-title":"Randomized controlled trial of oral glutathione supplementation on body stores of glutathione","volume":"54","author":"Richie","year":"2015","journal-title":"Eur J Nutr"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"108026","DOI":"10.1016\/j.neuropharm.2020.108026","article-title":"Oral glutathione administration inhibits the oxidative stress and the inflammatory responses in AppNL-G-F\/NL-G-F knock-in mice","volume":"168","author":"Izumi","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.redox.2015.07.012","article-title":"Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: a comparative crossover study","volume":"6","author":"Schmitt","year":"2015","journal-title":"Redox Biol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/ejcn.2017.132","article-title":"Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function","volume":"72","author":"Sinha","year":"2018","journal-title":"Eur J Clin Nutr"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/3286365","article-title":"Bioavailability study of an innovative Orobuccal formulation of glutathione","volume":"2016","author":"Buonocore","year":"2016","journal-title":"Oxidative Med Cell Longev"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2161-069X.1000462","article-title":"An orally-bioavailable glutathione-based Hepatoprotective compound in experimental acute liver injury: more effective than Silymarin and YHK","volume":"6","author":"Kantah","year":"2016","journal-title":"J Gastrointest. Dig. Syst"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/livers2010003","article-title":"Oxidative stress in non-alcoholic fatty liver disease","volume":"2","author":"Smirne","year":"2022","journal-title":"Liver"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.4254\/wjh.v7.i10.1325","article-title":"Oxidative stress: new insights on the association of non-alcoholic fatty liver disease and atherosclerosis","volume":"7","author":"Polimeni","year":"2015","journal-title":"World J Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0024-3205(89)90293-2","article-title":"Glutathione depletion by hyperphagia-induced obesity","volume":"45","author":"Sastre","year":"1989","journal-title":"Life Sci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1067\/mpd.2000.102940","article-title":"Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents","volume":"136","author":"Strauss","year":"2000","journal-title":"J Pediatr"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/0098-2997(93)90002-U","article-title":"The glyoxalase system in health and disease","volume":"14","author":"Thornalley","year":"1993","journal-title":"Mol Asp Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12953-018-0131-y","article-title":"Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease","volume":"16","author":"Spanos","year":"2018","journal-title":"J Proteome Sci"},{"key":"ref42","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.68417","article-title":"\u2018Impact of Glyoxalase-I (Glo-I) and Advanced Glycation End Products (AGEs) in Chronic Liver Disease\u2019","volume-title":"Liver Cirrhosis - Update and Current Challenges, InTech","author":"Hollenbach","year":"2017"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/hep.20280","article-title":"Beyond insulin resistance in NASH: TNF-alpha or adiponectin?","volume":"40","author":"Hui","year":"2004","journal-title":"Hepatology"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jhep.2021.10.013","article-title":"Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease","volume":"76","author":"Luukkonen","year":"2022","journal-title":"J Hepatol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e1008629","DOI":"10.1371\/journal.pgen.1008629","article-title":"A missense variant in mitochondrial Amidoxime reducing component 1 gene and protection against liver disease","volume":"16","author":"Emdin","year":"2020","journal-title":"PLoS Genet"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/gut.48.2.206","article-title":"The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis","volume":"48","author":"Wigg","year":"2001","journal-title":"Gut"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/jgh.12019","article-title":"Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis","volume":"28","author":"Roh","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1053\/j.gastro.2008.10.080","article-title":"Microbes in gastrointestinal health and disease","volume":"136","author":"Neish","year":"2009","journal-title":"Gastroenterology"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.cgh.2012.03.011","article-title":"Features, diagnosis, and treatment of nonalcoholic fatty liver disease","volume":"10","author":"Torres","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12944-017-0613-4","article-title":"Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis","volume":"16","author":"Du","year":"2017","journal-title":"Lipid Health Dis"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/hep.20023","article-title":"Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver","volume":"39","author":"Bugianesi","year":"2004","journal-title":"Hepatology"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1111\/j.1572-0241.2007.01192.x","article-title":"Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study","volume":"102","author":"Valenti","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2021.03.014","article-title":"Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD","volume":"75","author":"Corradini","year":"2021","journal-title":"J Hepatol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.20517\/2394-5079.2021.03","article-title":"Systematic review of existing guidelines for NAFLD assessment","volume":"7","author":"Monelli","year":"2021","journal-title":"Hepatoma Res"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/1751-2980.12685","article-title":"Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)","volume":"20","author":"Fan","year":"2019","journal-title":"J Dig Dis"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J Hepatol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"M\u00f3zes","year":"2022","journal-title":"Gut"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/hep.29465","article-title":"Altered amino acid concentrations in NAFLD: impact of obesity and insulin resistance","volume":"67","author":"Gaggini","year":"2018","journal-title":"Hepatology"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"8082","DOI":"10.3748\/wjg.v20.i25.8082","article-title":"Oxidative stress as a crucial factor in liver diseases","volume":"20","author":"Cicho\u017c-Lach","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"17756","DOI":"10.3748\/wjg.v20.i47.17756","article-title":"Pathogenesis of alcoholic liver disease: role of oxidative metabolism","volume":"20","author":"Ceni","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radic Biol Med"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0741-8329(02)00229-X","article-title":"S-Adenosyl-L-methionine and mitochondrial reduced glutathione depletion in alcoholic liver disease","volume":"27","author":"Fern\u00e1ndez-Checa","year":"2002","journal-title":"Alcohol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1042\/CS20030285","article-title":"Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients","volume":"106","author":"Videla","year":"2004","journal-title":"Clin Sci (Lond)"},{"key":"ref70","first-page":"316","article-title":"Glutathione in the treatment of liver diseases: insights from clinical practice","volume":"62","author":"Sacco","year":"2016","journal-title":"Minerva Gastroenterol Dietol"},{"key":"ref71","first-page":"87","article-title":"Reduced gluthatione in alcoholic hepatophaty","volume":"14","author":"Massa","year":"1993","journal-title":"Giornale Ital Ricerche Clin Ter"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3109\/00365519609088799","article-title":"Effect of alcohol abuse and glutathione administration on the circulating levels of glutathione and on antipyrine metabolism in patients with alcoholic liver cirrhosis","volume":"56","author":"Loguercio","year":"1996","journal-title":"Scand J Clin Lab Invest"},{"key":"ref73","first-page":"47","article-title":"High-dose reduced glutathione in the therapy of alcoholic hepatopathy","volume":"136","author":"Nardi","year":"1991","journal-title":"Clin Ter"},{"key":"ref74","first-page":"753","article-title":"The use of reduced glutathione in alcoholic hepatopathy","volume":"82","author":"Bresci","year":"1991","journal-title":"Minerva Med"},{"key":"ref75","first-page":"195","article-title":"Ultrasound monitoring of alcholic liver steatosis during glutathione (GSH) treatment","volume":"42","author":"Scotto","year":"1996","journal-title":"Minerva Gastroenterol Dietol"},{"key":"ref76","first-page":"117","article-title":"The reduced gluthatione in the treatment of alcoholic chronic hepatopathy without cirrhosis","volume":"14","author":"Cagianelli","year":"1993","journal-title":"Giornale Ital Ricerche Clin Ter"},{"key":"ref77","first-page":"290","article-title":"Il glutatione nella terapia delle epatopatie croniche steatosiche [glutathione in the treatment of chronic fatty liver diseases]","volume":"86","author":"Dentico","year":"1995","journal-title":"Recenti Prog Med"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5005\/jp-journals-10018-1159","article-title":"Reduced glutathione suppresses oxidative stress in nonalcoholic fatty liver disease","volume":"6","author":"Irie","year":"2016","journal-title":"Eur J Hepatogastroenterol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12876-017-0652-3","article-title":"Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study","volume":"17","author":"Honda","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1124275\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T15:34:12Z","timestamp":1679499252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1124275\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":80,"alternative-id":["10.3389\/fmed.2023.1124275"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1124275","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]},"article-number":"1124275"}}